Development and characterization of a high-throughput in vitro cord formation model insensitive to VEGF inhibition by Beverly L Falcon et al.
JOURNAL OF HEMATOLOGY
& ONCOLOGY
Falcon et al. Journal of Hematology & Oncology 2013, 6:31
http://www.jhoonline.org/content/6/1/31RESEARCH Open AccessDevelopment and characterization of a
high-throughput in vitro cord formation model
insensitive to VEGF inhibition
Beverly L Falcon1, Belinda O’Clair4, Don McClure2, Glenn F Evans1, Julie Stewart3, Michelle L Swearingen1,
Yuefeng Chen1, Kevin Allard4, Linda N Lee1, Kuldeep Neote1, Dyke P McEwen4, Mark T Uhlik1 and
Sudhakar Chintharlapalli1*Abstract
Background: Anti-VEGF therapy reduces tumor blood vessels, however, some vessels always remain. These VEGF
insensitive vessels may help support continued tumor growth and metastases. Many in vitro assays examining
multiple steps of the angiogenic process have been described, but the majority of these assays are sensitive to
VEGF inhibition. There has been little focus on the development of high-throughput, in vitro assays to model the
vessels that are insensitive to VEGF inhibition.
Methods: Here, we describe a fixed end-point and kinetic, high-throughput stem cell co-culture model of cord
formation.
Results: In this system, cords develop within 24 hours, at which point they begin to lose sensitivity to VEGF
inhibitors, bevacizumab, and ramucirumab. Consistent with the hypothesis that other angiogenic factors maintain
VEGF-independent vessels, pharmacologic intervention with a broad spectrum anti-angiogenic antagonist (suramin),
a vascular disrupting agent (combretastatin), or a combination of VEGF and Notch pathway inhibitors reduced the
established networks. In addition, we used our in vitro approach to develop an in vivo co-implant vasculogenesis
model that connects with the endogenous vasculature to form functional blood vessels. Similar to the in vitro
system, over time these vessels become insensitive to VEGF inhibition.
Conclusion: Together, these models may be used to identify novel drugs targeting tumor vessels that are not
sensitive to VEGF inhibition.
Keywords: Angiogenesis, Vascular endothelial growth factor (VEGF), Adipose derived stem cells (ADSC), Endothelial
colony forming cells (ECFC)Background
Preclinical studies indicate that most solid tumors require
angiogenesis, the formation of new blood vessels from
existing vessels, for growth, survival, and metastasis.
While many factors regulate tumor angiogenesis, vascular
endothelial growth factor (VEGF) appears to have a dom-
inant role, inducing vascular permeability, endothelial cell
proliferation and migration, and new blood vessel growth.
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reproduction in any medium, provided the orpathway with receptor tyrosine kinase inhibitors, with sol-
uble decoy receptors, or with antibodies targeting the
VEGF ligand or receptor. Inhibition of VEGF signaling re-
duces tumor growth in many preclinical models [1,2],
however, the benefits of targeting VEGF in mouse models
have not completely translated to the clinic. While the
FDA has approved multiple VEGF pathway inhibitors for
clinical treatment of certain cancers, not all patients bene-
fit from these treatments. Some tumors may initially re-
spond but eventually become refractory, while others
show no clinical benefit of inhibiting the VEGF pathway
[3]. Some preclinical models have even shown resistanceLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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hibition [4-6].
Both preclinical and clinical studies have shown that
despite significant reductions in tumor blood vessels
with VEGF signaling blockade, some tumor blood vessels
remain [7,8]. The blood vessels that remain have a dis-
tinct phenotype typically associated with more pericyte
coverage [8-13]. There are a number of possible explana-
tions for this effect. First, the initial reduction in tumor
blood vessels leads to tumor cell hypoxia, which, in turn,
can cause tumor cells to either secrete more VEGF to
overcome the anti-VEGF therapy or stimulate the release
of other pro-angiogenic cytokines [4,14-16]. “Vascular
normalization” may also play a role in VEGF resistant
tumor vessels. VEGF inhibitors can transiently improve
pericyte and basement membrane coverage, decrease
tumor vessel tortuosity and hyperpermeability, and in-
crease oxygen and drug delivery [10,17,18]. These vessels
may be formed via normalization of the atypical pheno-
type associated with tumor vessels or a pruning of the
abnormal vessels leaving behind pre-existing vessels that
have a more normal phenotype. Studies by Hal Dvorak’s
group indicate that tumor blood vessels are heterogeneous
consisting of at least six distinctly different blood vessel
types: (1) “mother” vessels, (2) glomeruloid microvascular
proliferations, (3) vascular malformations, (4) capillaries,
(5) feeder arteries (6) and draining veins [19,20]. Interest-
ingly, only subpopulations of these vessels are sensitive to
VEGF inhibition. Immunodeficient mice expressing
VEGF-A164 initially form vessel subtypes such as “mother”
vessels and GMPs that are sensitive to VEGF inhibitors
while later stage vessels are VEGF-independent [20,21].
Thus, the developmental stage of tumor vasculature is
critical to anti-VEGF therapy sensitivity and the lack of
good in vitro resistance models has slowed the develop-
ment of non-VEGF anti-angiogenic therapies. In particu-
lar, studies should be developed to identify novel ways of
targeting the tumor blood vessels that remain or are in-
sensitive to VEGF inhibition.
Many in vitro assays have been developed that examine
multiple steps in the angiogenic process. These assays inter-
rogate sprouting and tip formation, migration and prolifera-
tion, lumen formation, and tube or cord formation. In vivo
assays also look at many of these similar processes. The ma-
jority of these assays, however, are driven by the addition of
VEGF or other growth factors to the system and remain
sensitive to VEGF inhibition [22-25]. Disrupting established
vessels, cords, or tubes which may be insensitive to VEGF
inhibitors, however, has not been a major focus of in vitro
or in vivo approaches. Here, we describe an in vitro cord for-
mation assay that demonstrates insensitivity to VEGF inhib-
ition. Similar to what is seen in vivo, resistance to VEGF
inhibition is associated with cord maturity and pericyte asso-
ciation. The advantage of this approach is its increasedthroughput and ability to identify novel anti-angiogenic
agents that can inhibit VEGF-independent vessels. Finally,
we show the translatability of this in vitro approach using an
in vivo model of vasculogenesis to validate the effectiveness
of novel treatments on the ability to decrease blood vessels
that are insensitive to VEGF inhibition.
Results
Characterization of multiple in vitro angiogenesis models
Multiple in vitro models of angiogenesis or cord formation
were examined (Figure 1). Traditionally, co-cultures of
HUVECs and NHDFs have been used to analyze and quan-
tify growth factor and drug effects on angiogenesis [26].
Recently, a co-culture model of ECFCs and ADSCs, which
has a shorter experimental duration and presence of
pericyte biology, has been described [22]. In all of the
models examined, cord formation occurred in the controls
with increased cord formation induced by 20 ng/mL VEGF
(Figure 1a). We observed a 44% increase in cords in the
NHDF/HUVEC co-culture model while there was a 76%
increase in cords in the ADSC/ECFC co-culture model at
this VEGF concentration (Figure 1a). The optimized media
used for these assays, however, contain serum and angio-
genesis related growth factors such as epidermal growth
factor (EGF) and basic fibroblast growth factor (FGF). In
order to reduce background cord formation and increase
responsiveness to exogenously added angiogenic growth
factors, a basal media (BM) was developed which lacks
serum and any additional growth factors. When the
ADSC/ECFC co-culture was run in BM, the background
cord formation decreased by 68% and there was a 194% in-
crease in cord formation with the addition of VEGF
(Figure 1a). Immunocytochemical characterization showed
that cords formed in the ADSC/ECFC co-cultures express
multiple markers common to the in vivo vasculature
[27-29] (Figure 1b). CD31 (PECAM-1), VEGFR-2, and VE-
cadherin were expressed by the endothelial cells forming
the cords (Figure 1b). In addition, only ADSCs that were in
close proximity with endothelial cells differentiated into
cells expressing SMA and PDGFR-β, indicative of a
pericyte-like phenotype [28] (Figure 1b, arrows). These
pericyte markers were not expressed in the ADSC feeder
layer found away from the cords. Finally, vascular base-
ment membrane markers, such as nidogen and type IV col-
lagen, were expressed and associated with the cords in this
co-culture system (Figure 1b). In contrast, in the NHDF/
HUVEC co-culture model, the cords expressed endothelial
and basement membrane markers, but pericyte markers
were not expressed (data not shown).
Time course of ADSC/ECFC cord formation
To further characterize the development of basal and
VEGF-induced cords and its associated SMA cells,
ADSC/ECFC co-cultures were examined from 0–7 days
Figure 1 Characterization of co-cultured cord formation assays. (a) Unstimulated or VEGF-stimulated (20 ng/mL) cords stained with CD31
from co-cultures of NHDFs and HUVECs (top left), ADSCs and ECFCs in optimized medium (top right), and ADSCs and ECFCs grown in basal
medium (bottom left). Graph compared the total tube areas of the cords from the different assay systems. n = 3–5 per group. * = p < 0.0001 vs.
respective control. (b) Images of 5d ADSC and ECFC cords grown in basal medium and stimulated with 20 ng/mL VEGF. Endothelial cells were
labeled with CD31, VEGFR-2, or VE-cadherin (top), mural cells or pericytes were labeled with SMA or PDGFR-β (middle), and vascular basement
membrane was identified by nidogen and type IV collagen antibodies (bottom). Arrows indicate areas where pericytes labeled with SMA or
PDGFR-β were associated with the cords.
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VEGF-induced cords have already formed. The basal
cords were only stable for a few days, before reductions
in total tube area were seen beginning around day 3.
VEGF-induced cords were stable over the 7 day time
course with slight increases in total tube area after the
first 24 hours (Figure 2a and b). The increase in SMA
index was not observed until day 3, and increaseddramatically over the next 48 hours (Figure 2a and b).
These results indicate that VEGF-induced cords are ini-
tially formed within the first day. After the first day,
however, the cords appear to remodel and may become
more stable by the differentiation of the ADSCs into
SMA expressing pericyte-like cells.
Continuous monitoring of cord formation using GFP-
expressing ECFCs cultured with ADSCs demonstrated
Figure 2 Time course of cord formation in ADSC and ECFC co-cultures grown in basal medium. (a) Images of endothelial cells stained
with CD31 and SMA-positive pericytes in the ADSC/ECFC co-culture assay system either unstimulated (basal; top) or stimulated with 20 ng/mL
VEGF (bottom) at 0, 1, 3, 5, and 7 days. (b) Graphs of a time course from 0–7 days showing total tube area of the cords (left) and its associated
SMA index (right). (c) Continuous monitoring of the tube length per unit area of GFP labeled ECFCs in the ADSC/ECFC co-culture assay system in
basal media plus with no stimulation (gray) or a concentration response of VEGF from 0 to 102 hours.
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cord formation (Figure 2c). Similar to the fixed endpoint
studies, the increased VEGF induced cord formation was
found in the first 24–36 hours. After 36 hours, the
higher concentrations of VEGF-induced cords were
stable over the next 3 days (Figure 2c).
Targeting the components of the cord formation system
To determine whether VEGF-induced cords can be
targeted with anti-VEGF therapy, cords were treated with a
receptor tyrosine kinase inhibitor targeting the VEGFreceptors among others (sunitinib), an antibody targeting
the VEGF-A ligand (avastin; bevacizumab), or an antibody
targeting VEGFR-2 (IMC-1121B; ramucirumab) (Figure 3a).
Blocking VEGF signaling with sunitinib, bevacizumab, or
ramucirumab all concentration-dependently reduced
VEGF-driven cord formation in the ADSC/ECFC co-
culture system. Sunitinib (0.2 μM) maximally decreased
VEGF-induced total tube area by 89% (EC50 = 0.027 μM),
bevacizumab (20 μg/mL) by 65% (EC50 = 0.174 μM), and
ramucirumab (20 μg/mL) by 80% (EC50 = 0.623 μM)
(Figure 3a and b). In addition to VEGF-induced cords,
Figure 3 Targeting cord formation or pericyte association in the ADSC/ECFC co-culture model. (a) CD31 stained basal or VEGF stimulated
cords at 3 days treated with 2 μM Sunitinib, 20 μg/mL bevacizumab (Bev), or 20 μg/mL ramucirumab (Ram). (b) Graphs of a concentration
response of sunitinib, bevacizumab (Bev), and ramucirumab (Ram) on total tube area of basal and VEGF stimulated cord formation after 3 days.
(c) VEGF stimulated cords were established for 4 days then treated with control or a PDGFR-β inhibitor, IMC-2C5 (2C5) for 3 days. Images show
the effects of control and IMC-2C5 on VEGF stimulated endothelial cords stained with CD31 (green) and SMA-positive pericytes (red). (d) Graphs
of total tube area (left) and SMA index (right) of VEGF stimulated cords with or without PDGFR-β inhibition. n = 3 per group. * = p < 0.001 vs.
Control. † = p < 0.01 vs. VEGF.
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area by 75% and 72% respectively, while bevacizumab
only decreased basal cords by 10% (Figure 3a and b).
While the inhibitors of VEGF signaling decreased cord
formation in a concentration-dependent manner, even
at the highest concentrations, cords were not completely
eliminated. This may indicate that the remaining cords
are dependent on other growth factors secreted by thefeeder layer of ADSCs. In fact, examination of cords
indicate that the basal cords formed in the ADSC/ECFC
co-culture system are also dependent on HGF [22]
(Additional file 1: Figure S1).
The ability to target SMA positive pericyte differenti-
ation was also examined. Previous studies indicate that
PDGF expression and stimulation of its receptor, PDGFR-
β, are important for pericyte recruitment [30-32]. Here,
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pericyte differentiation. After 4 days, the cords were
treated with 20 μg/mL IgG1 or a PDGFR-β blocking anti-
body (IMC-2C5; [33]). Inhibition of PDGFR-β signaling
with IMC-2C5 decreased the SMA index induced by
VEGF by 79%, indicating a reduction in pericyte coverage,
but the total tube area was not affected (Figure 3c and b).
Development of VEGF insensitive cords
To determine whether cords remain sensitive to inhibi-
tors of VEGF signaling, VEGF-induced cords were
allowed to establish for 0, 1, 2, or 4 days prior to
addition of bevacizumab or ramucirumab. BevacizumabFigure 4 VEGF stimulated cords become insensitive to inhibitors of V
established for 0, 1, 2, or 4 days, then treated with a concentration respons
areas for each were graphed. (b) Continuous monitoring of the effect of a
beginning on day 0 (neoangiogenic mode; top) or after 4 days of establish
effect of a concentration response of ramucirumab (Ram) on cord tube len
establishment (established mode; bottom).(20 μg/mL) decreased total tube area by 64% when given
on day 0, by 25% on day 1, 13% on day 2, and 16% on
day 4 (Figure 4a). Cord formation was reduced by 75%
when ramucirumab (20 μg/mL) was given on day 0, 33%
on day 1, 21% on day 2, and 18% on day 4 (Figure 4a).
These results indicate that once established, cords
become increasingly resistant to VEGF inhibition. To
further characterize this insensitivity to VEGF inhibition,
continuous live-cell monitoring of the cords after
ramucirumab or bevacizumab treatment at day 0
(neoangiogenic mode) or day 4 (established mode) was
compared (Figure 4b and c). Bevacizumab (25 μg/mL) de-
creased neoangiogenic cord formation by 70%, but onlyEGF signaling in the ADSC/ECFC co-culture model. (a) Cords were
e of bevacizumab (Bev; left) or ramucirumab (Ram; right). Total tube
concentration response of bevacizumab (Bev) on cord tube length
ment (established mode; bottom). (c) Continuous monitoring of the
gth beginning on day 0 (neoangiogenic mode; top) or after 4 days of
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Likewise, ramucirumab treatment (10 μg/mL) decreased
neoangiogenic cord formation by 90% and only decreased
established cord formation by 30% (Figure 4c).In vivo model of VEGF insensitive vessels
A limitation of any in vitro model is its translatability to
in vivo biology. Here, to investigate whether similar
VEGF-independent vessels can be established in vivo, a
co-implant model of in vivo vasculogenesis with ADSCs
and ECFCs was performed. Injection of a mixture of
ADSCs and ECFCs in Matrigel develop blood vessels
within 3 days. Evidence of blood perfusion (identified
with an erythrocyte marker, TER119) in the vessels was
seen beginning at 4 days and increased with additional
time (Figure 5a and b). At 6 days, however, evidence of
hemorrhage, or TER119 not associated with blood
vessels became evident (Figure 5a, arrows). Four-dayFigure 5 In vivo model of vasculogenesis develops VEGF-independen
ECFCs co-implanted into the flank develop blood vessel like structures stain
blood cells (erythrocytes; TER119) associated with the vessels beginning on
staining not associated with the blood vessels were seen (arrows). (b) Grap
with erythrocytes (TER119) after 3–6 days of growth in the flank of a mous
Images of blood vessels stained with CD31 within the implants after treatm
4 days (bottom) of establishment. (d) Graph of the percent area of CD31 a
or day 4. n = 10 per treatment group. * = p < 0.0001 vs. all other treatmenttreatment with ramucirumab beginning on day 0 de-
creased the percent area of CD31 by 81%. However,
when ramucirumab treatment was given for 4 days
beginning on day 4, the percent area of CD31 was only
reduced by 24% (Figure 5c and d); recapitulating the
in vitro observations.Targeting VEGF-independent cords
A number of different mechanisms, including the
upregulation of other angiogenic pathways such as the
Notch pathway, have been described to play a role in the
development of tumor vessels that are insensitive to
anti-VEGF therapy [4,14,15,34]. To determine whether
other classes of anti-vascular therapy can reduce
cords that are insensitive to VEGF inhibition, a broad
spectrum anti-angiogenic antagonist (suramin), a vascu-
lar disrupting agent (combretastatin), and a combination
therapy of a VEGFR-2 inhibitor (ramucirumab) and at cords. (a) An in vivo model of vasculogenesis in which ADSCs and
ed with CD31. The vessels anastamose with the host vessels and have
day 4. At later times, however, hemorrhage indicated by TER119
h of the percent area of CD31 and the percent of vessels associated
e. n = 8 per group. * = p < 0.05 vs. day 3. † = p < 0.01 vs. day 4. (c)
ent with IgG or ramucirumab (Ram) beginning on day 0 (top) or after
fter 4 days of treatment with IgG or ramucirumab beginning on day 0
groups. † = p < 0.01 vs. all other groups.
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tested on established cords (Figure 6). VEGF-induced cords
were allowed to establish for 4-days prior to addition of sura-
min, combretastatin, or the ramucirumab/GSI (LY411575)
combination. Suramin treatment (100 μM) decreased
VEGF-established cords by 90% (Figure 6a), combretastatin
(11 nM) decreased cords by 100% (Figure 6b), and the com-
bination of ramucirumab (10 μg/mL) and a GSI (LY411575;
10 nM) decreased established cords by 50% (Figure 6c). The
reduction in established cords with the combination of
ramucirumab and a GSI (LY411575) was greater than eitherFigure 6 Targeting the VEGF-independent cords. VEGF stimulated ADSC
response of suramin (a) or combretastatin (b). The effects on the tube length o
drug addition. (c) Continuous monitoring of the effect of ramucirumab (Ram),
on the tube length of 4 day established cords. (d) Images of blood vessels stai
(Ram), a gamma secretase inhibitor (GSI; LY411575), or the combination of Ram
percent area of CD31 after 4 days of treatment beginning on day 4 (right). n =
other groups.of the drugs alone (Figure 6c). Similarly, in the co-implant
model of in vivo vasculogenesis, ramucirumab or the GSI
(LY411575) alone led to slight reductions in vessels that were
allowed to establish for 4 days prior to treatment. However,
the combination of ramucirumab and the GSI (LY411575)
almost completely eliminated the vessels (Figure 6d).
Discussion
Results from this study indicate that a co-culture system
of progenitor cells and endothelial cells can create a cord
network with components found in the vasculature:/ECFC co-cultures established for 4 days were treated with a concentration
f the established cords were continuously monitored from the day of
a gamma secretase inhibitor (GSI; LY411575), or the Ram/GSI combination
ned with CD31 within the implants after treatment with IgG, ramucirumab
and the GSI beginning after 4 days of establishment (left). Graph of the
10 per treatment group. * = p < 0.01 vs. hIgG control. †= p< 0.001 vs. all
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Exogenously added VEGF can stimulate cord formation
and the cords that develop become insensitive to VEGF
inhibition as the cords mature. An in vivo co-implant
model of vasculogenesis, using the same progenitor and
endothelial cells as the in vitro approach, develops func-
tional blood vessels that anastamose with the host vascu-
lature. These vessels also become insensitive to VEGF
pathway inhibition with time. Together, these studies in-
dicate that the combined use of an in vitro high-
throughput established cord formation assay and an
established in vivo co-implant model of vasculogenesis
can be used to identify novel drugs that can target
VEGF-independent blood vessels.
Here, we investigate two different in vitro models of
angiogenesis. The first model uses co-cultures of human
umbilical vein endothelial cells (HUVEC) with normal
human dermal fibroblasts (NHDF) and the other uses
co-cultures of endothelial colony forming cells (ECFC)
with adipose-derived stem cells (ADSC). When seeded
with NHDF, the HUVECs recapitulate the major phases of
the angiogenic process, initially proliferating and migrat-
ing into endothelial clusters followed by differentiation
and branching into complex networks over the 7–10 day
assay. Under basal conditions, little tube formation occurs,
while VEGF addition on day 3–4 stimulates tube forma-
tion in a concentration-dependent manner [37-39]. Fur-
ther characterization of the HUVEC/NHDF approach
shows that the pharmacological and physiological effects
on endothelial cell biology are highly translatable to previ-
ous in vivo characterizations, exemplified by DLL4/Notch
inhibition resulting in increased branch point formation
late in the angiogenic process [39-41]. One of the major
advantages of the ADSC and ECFC co-culture model is
that the process of developing cords occurs quickly and
incorporates a pericyte-like biology associated with the
cords. Unlike the NHDF/HUVEC model and other similar
models, in the ADSC/ECFC model, the majority of VEGF-
driven cords are formed within the first 24 hours
[23,24,38,42]. Additional stimulation allowed for further
remodeling of the vessels and differentiation of the
ADSCs into SMA or PDGFR-β expressing pericyte-like
cells. Characterization of these SMA associated cords
indicates that drugs targeting VEGF or PDGF can in-
hibit the cords or the pericytes, respectively, similar to
what has previously been shown in vivo [8,28]. Further,
VEGF is not the only growth factor that induces rapid
cord formation. Other pro-angiogenic growth factors,
including FGF and EGF, also induce cord formation in
a concentration-dependent manner and exhibit differ-
ent phenotypes and kinetics (manuscript under prepar-
ation). In addition to the assay duration and the cord
similarities to in vivo vascular structure, the use of
basal media in the ADSC/ECFC co-culture assay hasdramatically increased the response window for drug
screening purposes.
Interestingly, we found that inhibition of the VEGF re-
ceptor with sunitinib or ramucirumab leads to decreases
in basal and VEGF driven cord formation, but inhibition
of the ligand with bevacizumab only affected the VEGF
driven cords. There may be several explanations for this
effect. Endothelial cells can make VEGF and signal in an
autocrine fashion. In fact, previous studies using endothe-
lial cell specific knockout of VEGF indicates that autocrine
VEGF signaling is required for the homeostasis of blood
vessels [43]. It is also feasible that ligand-independent
mechanisms or signaling through heterodimerization of
VEGFR2 with other receptors may play an important role
in basal cord formation [44]. Internalization of the recep-
tor with ramucirumab or the multi-targeted nature of
Sunitinib may play a role as well. Finally, VEGF secreted
in the co-culture system may get bound to the extracellu-
lar matrix, where it may not be accessible to VEGF anti-
bodies, but may still be able to be affected by receptor
inhibition. These possibilities require further exploration
as it is unclear what mechanism or mechanisms are in-
volved in the ECFC/ADSC co-culture assay.
Unlike most tube and cord formation assays, established
cords in the ADSC and ECFC co-culture system lose their
dependence on VEGF once the cords are developed. Even
after 1 day of establishment, the cords are less sensitive to
multiple inhibitors of the VEGF signaling pathway. The
mechanism of this VEGF-independence is not clear.
Pericyte coverage is thought to make vessels insensitive to
VEGF inhibition, but in this assay, we see increased VEGF
independence after 1 day even though the SMA differenti-
ation does not occur until day 3. In addition, inhibition of
the PDGFR after 4 days of establishment decreased the
SMA index but did not significantly alter total tube area.
While it is still possible that pericytes play an important
role in maintenance of established vessels, in this assay
system other growth factors secreted by the ADSC feeder
layer likely play a major role in maintaining the cords once
they have been created. Clearly, there are some cords that
can form without the addition of VEGF. Previous studies
and our data indicate that HGF is highly expressed by the
ADSCs and contributes to basal cord formation [22]. In
vivo studies show that inhibition of VEGF and the HGF
receptor, c-Met, decrease tumor vessels more than VEGF
inhibition alone [29]. Together, these results indicate that
the HGF secreted by the feeder layer may have an import-
ant role in maintenance of the established cords. In
addition, we show that suramin, a broad-spectrum antag-
onist that inhibits various angiogenesis-related growth fac-
tors such as insulin-like growth factor, epidermal growth
factor, platelet-derived growth factor, VEGF, and basic
fibroblast growth factor, is able to reduce the VEGF-
independent cords. Together, these results indicate that
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feeder layer may maintain cords following the initial
VEGF stimulation.
Using an in vivo co-implant model of vasculogenesis
with ADSCs and ECFCs, functional vessels can form
after anastamosing with the host vasculature. These ves-
sels form over 3 days and blood cells labeled with
TER119 can be seen beginning 4 days after the cells are
injected into the flank. Treatment of the vasculogenic
plugs with a VEGF inhibitor dramatically decreases
blood vessel formation if given at the beginning of the
assay. If, however, VEGFR signaling was not inhibited
until the vessels have established and have blood flow (at
day 4), there is little effect. While the mechanism of this
insensitivity is not know, it would be interesting to
characterize our VEGF independent vessels to determine
whether they have similar phenotypes as those described
by the Dvorak laboratory [20,21]. Nonetheless, these re-
sults are consistent with our high-throughput in vitro
assay and provide a unique in vivo model to examine the
effects of novel drugs on vessels that are insensitive to
VEGF inhibition.
As proof of principle, a broad-spectrum anti-angiogenic in-
hibitor (suramin), a vascular disrupting agent (combretastatin),
and a combination of a gamma secretase and VEGF in-
hibitor were tested on VEGF established cords. Suramin
blocks a variety of growth factors including many
angiogenesis-related factors. One of the proposed mecha-
nisms of VEGF-independent tumor vessels is that inhib-
ition of VEGF leads to induction of other proangiogenic
factors [4,14,15,34]. Suramin is likely able to block many
of these other proangiogenic factors to reduce the cords
in our established cord assay system.
The vascular disrupting agent combretastatin is a
microtubule-depolymerizing agent which binds to tubulin
dimers to prevent microtubule polymerization. This re-
sults in mitotic arrest and apoptosis of endothelial cells. In
addition, combretastatin disrupts the endothelial cell junc-
tion molecule (VE-cadherin) leading to vascular collapse
[45] and in vivo studies show that combretastatin is able
to reduce immature vessels [45,46]. We observed reduc-
tions in established cords with combretastatin treatment.
Clearly, while combretastatin may not reduce all mature
vessels in vivo, it is able to target a unique population of
vessels or cords that are insensitive to VEGF inhibition. In
fact, preclinical and clinical studies indicate that combin-
ing combretastatin with bevacizumab is more efficacious
than either inhibitor alone [47,48].
A recent in vivo study indicates that VEGF-independent
vessels are driven by DLL4-Notch signaling and are sensi-
tive to gamma secretase inhibition [34]. Consistent with
this novel strategy to overcome anti-angiogenic resistance,
a gamma secretase inhibitor was tested in our in vitro and
in vivo models alone or in combination with inhibition ofVEGF signaling. In the in vitro system, treatment with ei-
ther compound alone prevented a slight increase in cords
associated with feeding the cells with fresh VEGF, but did
not disrupt established networks. However, when VEGF
and gamma secretase inhibitors were combined, there was
a reduction in the number of cords. Similarly, in the
in vivo co-implant model, ramucirumab or the gamma
secretase inhibitor alone elicited a slight reduction in the
vessels, but the combination reduced the vessels signifi-
cantly more. These results indicate that our established
cord assays may be used to identify new pathways in-
volved in anti-VEGF/VEGFR directed therapy resistance
and potential combinatorial strategies.
Many current angiogenesis assays used to screen anti-
angiogenic agents are highly VEGF dependent. However,
from preclinical and clinical analysis, there clearly exists
a population of tumor vessels that are insensitive to
VEGF inhibition. Thus, angiogenic assays are needed in
which novel agents can be tested for their effectiveness
on vessels which are not dependent on VEGF. The
ECFC/ADSC assay is high throughput and relatively
quick. Results can be obtained in approximately a week
and can be run in 96-well and 384-well formats and
similar co-culture approaches have previously been used
in high-throughput drug discovery [24,49]. In addition,
labeling the ECFCs with GFP is a feasible approach to
monitor cord formation and effects on established cords
using continuous live-cell monitoring. Together, these
results indicate that a co-culture cord formation system
with ADSCs and ECFCs is a useful method to identify
and characterize novel drugs on VEGF-independent
cords. It would be interesting to identify selective
markers on tumor vessels that remain after VEGF ther-
apy and determine if the same markers exist in this co-
culture system. If so, these in vitro and in vivo systems
would be conducive to interrogate the mechanisms by
which vessels become insensitive to VEGF inhibition
though use of shRNA/siRNA knockdowns. With more
and more studies being published regarding mechanisms
of VEGF resistance, additional targets should be tested
in this in vitro co-culture system.
Conclusions
Despite in vivo evidence that VEGF independent vessels
exist, the majority of the in vitro assays used are
dependent on VEGF. We described an in vitro cord for-
mation assay that shows insensitivities to inhibition of
the VEGF pathway. In addition, we were able to show
the translatability of this assay using an in vivo model of
vasculogenesis. Together, the combined use of this
in vitro high-throughput established cord formation
assay and an established in vivo co-implant model of
vasculogenesis can be used to identify novel drugs that
can target VEGF-independent blood vessels.
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Cell lines and media
Human adipose derived stem cells (ADSCs) isolated
from lipoaspirates collected during surgical liposuction
procedures were purchased from Lonza (Allendale, NJ).
Cells were grown in EGM2-MV media (Cambrex;
Walkersville, MD) and used at passage 4–6. Endothelial
colony forming cells (ECFCs) isolated from cord-blood
derived endothelial cells were grown on Collagen I
coated flasks in EGM2-MV media supplemented with an
additional 5% FBS and used at passage 7–10 (Lonza).
For studies examining cord formation over time with
continuous live-cell monitoring, ECFCs were lentivirally
transduced to express CytoLight Green, a soluble variant
of GFP, and optimized for imaging in the IncuCyte™ im-
aging system. Human umbilical vein endothelial cells
(HUVECs) and normal human dermal fibroblast
(NHDF) cells and media were purchased from Cambrex.
HUVECs were grown in EGM media with 10% FBS and
NHDF cells were maintained in EGM-2 media.
Co-culture assay of endothelial cells and fibroblasts
HUVEC and NHDF co-culture cord formation assays
were performed with AngioKit optimized media (TCS
Cellworks, Birmingham, UK) as previously described
[26,37-39]. Briefly, 20K NHDF cells in 100 μL of media
were plated in each well of a 96-well plate and incubated
overnight at 37°C, 5% CO2. The next day, HUVECs were
added on top of the NHDF cells at 1800 cells/well in
100 μL and incubated overnight at 37°C, 5% CO2. On
the third day and every subsequent third day, the media
was changed to optimized media containing 20 ng/mL
VEGF (R&D Systems). On day 10, the co-culture was
fixed, stained, and imaged as described below.
Neoangiogenic ADSC and ECFC co-culture cord formation
assay
ADSC and ECFC co-culture assays were performed with
AngioKit optimized media, basal media (MCDB-131
medium with 30 μg/mL L-ascorbic acid 2-phosphate,
1 μM dexamethasone, 50 μg/mL tobramycin, 10 μg/mL
r-transferrin AF, and 10 μg/mL insulin) or basal media
plus (MCDB-131 medium with 0.3% FBS, 30 μg/mL L-
ascorbic acid 2-phosphate, 50 μg/mL tobramycin, 10 μg/
mL r-transferrin AF, and 10 μg/mL insulin). ADSCs were
plated in 96-well plates at 40–50K cells per well in
100 μL and incubated overnight at 37°C, 5% CO2. The
next day, the media was removed and 4–5K ECFCs per
well in 50–100 μL of media was plated on top of the
ADSC monolayer and incubated at 37°C, 5% CO2 for 3–
6 hours before the addition of growth factors and inhibi-
tors. After the ECFCs attach, growth factors and test
agents were added to the 50–100 μL of media at 2–5× to
achieve the final concentrations as indicated. Co-cultureswere grown for 0–7 days at which time the cells were
fixed, stained, and imaged as described below.
Established ADSC and ECFC co-culture cord formation
assay
Established ADSC and ECFC co-culture assays were
plated as described above for the neoangiogenesis assay.
After the ECFCs were allowed to attach, 20 ng/mL VEGF
was use to stimulate and establish the cord network. After
1–4 days the media was changed to contain fresh VEGF in
the presence or absence of inhibitors at the indicated con-
centrations. After addition of the inhibitors, cultures were
allowed to grow an additional 3–4 days before the cells
were fixed, stained, and imaged as described below to in-
vestigate network disruption or cord regression.
Fixation and staining of fixed endpoint cords
At the completion of the assay, ADSC/ECFC cords were
fixed and permeabilized with either 70% ice cold ethanol
for 20–30 minutes or 3% paraformaldehyde for 10 mi-
nutes followed by 70% ice cold ethanol for 20 minutes.
Cells were blocked with PBS + 1% bovine serum albu-
min (BSA) for 30 minutes at room temperature. Primary
antibodies were diluted in PBS + 1% BSA and stained ei-
ther sequentially or in combination for >90 minutes at
37°C. Endothelial cells were identified with sheep anti-
CD31 (PECAM-1; Sigma; 1:200), rabbit anti-VEGFR-2
(55B11; Cell Signaling; 1:50), or goat anti-VE-cadherin
(Santa Cruz; 1:50) antibodies. Cy3 conjugated mouse
anti-smooth muscle actin (SMA; Sigma; 1:200) and
rabbit anti-platelet-derived growth factor receptor beta
(PDGFR-β; Y92; LifeSpan; 1:50) antibodies identified
pericytes associated with the cords. Vascular basement
membranes were identified with goat anti-Nidogen
(R&D Systems; 1:50) and goat anti-type IV collagen
(Millipore; 1:50) antibodies. After a brief wash, second-
ary AlexaFluor 488- and 555-conjugated donkey anti-
sheep, donkey anti-rabbit, donkey anti-goat secondary
antibodies (Invitrogen; 1:400) were incubated for ~60
minutes at room temperature. Nuclei were identified
with Hoechst 33342 (Invitrogen; 1:1000) for 5 minutes
at room temperature. After Hoechst staining, the cells
were washed and imaged as described below.
Fixed endpoint imaging and quantification
Cord formation images were captured using a Cellomics
Arrayscan VTI and analyzed with the Tube Formation
bio-application reading at a magnification of 5×. Objects
were identified using an algorithm to detect CD31 stain-
ing of cords. Total tube area was calculated from 9 fields
for each well with 3–4 wells for each treatment. SMA
index was calculated from the intensity of the SMA
staining and related to the number of cords/tubes.
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ADSCs and ECFCs transduced with CytoLight Green
were seeded for the assay as described above. After 3–4
hours at 37°C, the cells were treated with test reagents
(growth factors ± compounds or antibodies), placed into
the IncuCyte FLR for imaging, and allowed to form net-
works over the course of the 4 day experiment. If run-
ning the assay in neoangiogenic mode, looking at the
inhibition of tube formation, the assay was terminated at
the 96 hour time point. If studying tube regression was
desired, the assay was run in established mode. To do
this, growth factor-driven networks were formed over
the first 96 hours of the assay. At this point, a full media
replacement occurred including fresh growth factor in
the presence or absence of test agent. The assay plate
was then placed back in the IncuCyte FLR and imaged
over the desired time frame to quantify regression of
established networks.
For imaging and quantification, phase-contrast and
fluorescent images were automatically collected every 6
hours in the IncuCyte FLR to detect network formation
using the Tiled Field of View (FOV) mosaic imaging
mode. The integrated Angiogenesis Analysis Module
was used to identify the fluorescent signal from back-
ground in order to quantify multiple assay metrics, such
as tube length and branch formation, for each time
point. In the first step of the process, the angiogenesis
algorithm analyzed each fluorescent image and assigned
a segmentation mask that closely resembles the in vitro
network. From here, the mask was refined and filtered
to exclude non-tube forming events, specifically measur-
ing angiogenesis over time. Kinetic plots of the angio-
genesis metrics was generated using the IncuCyte
software, allowing for a direct comparison of test agent
treatments to validated control conditions (Figure 2b).
In vivo vasculogenesis assay
ADSCs and ECFCs were mixed in a ratio of 1:4 (0.5 ×
106/2 × 106 cells/mL) in Matrigel (BD Biosciences) and
injected (0.2 mL/implant) subcutaneously into the flank
of female athymic nude mice as previously described
[50,51]. Three to six days following implantation, im-
plants were collected and placed into zinc-tris fixative.
Treatments with IgG or IMC-1121B (ramucirumab;
10 mg/kg, ip) began on day 0 or day 4. Treatments with
the gamma secretase inhibitor (GSI, LY411575; 3 mg/kg
QD, ip) alone or in combination with ramucirumab
began on day 4. The concentration of drugs used was
determined from dose response studies (data not
shown). Implants were collected and fixed 4 days post
treatment and analyzed using multiplexed immunohisto-
chemistry of sections stained for endothelial cells with a
CD31 antibody (PECAM; Bethyl; 1:50), erythrocytes with
a TER-119 antibody (BD Biosciences; 1:50), and nucleiwith Hoechst 33342 (Invitrogen; 1:1000). Quantifications
were made using an iCys research imaging cytometer as
previously described [52].
Statistical analysis
All experiments had an n ≥ 3 for each treatment and
similar results were seen in at least two experiments. Re-
sults are expressed as means ± SEM. Statistical differ-
ences were measured by ANOVA with a Tukey posthoc
test using JMP software.
Additional file
Additional file 1: Figure S1. Role of HGF in basal cords CD31 stained
basal cords at 3 days treated with 10 μg/mL hIgG or anti-HGF antibody.
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